[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2026",
    "title": "Kvartalsrapport Q4 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a282bcf2cda2ef27a9ceecc51f4a75b2a",
    "date": "2026-07-02",
    "period": "2026-q4",
    "form_type": "interim-report",
    "report_key": "2026:q4",
    "filename": "Cinclus_Pharma_has_Reached_Enrollment_Target_in_Phase_III_HEEALING1_Study_-_Topline_Results_Expe.pdf",
    "text_chars": 7132,
    "sha256": "a3ade84f3ebb56a475e5d9cba22fbf945d71ded11eb8759c7ce1f445395c7780",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/part-001.html",
        "chars": 7132
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac6dcc7bbc6692a0f752605df5f04d8c7",
    "date": "2026-05-13",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "Delarsrapport_Januari_Mars_2026.pdf",
    "text_chars": 62470,
    "sha256": "f3311b7e233e8d622d65baec7fcfd20c6cfb20db47f5867b579282da6260950f",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 62470
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a76f761d15875030f49691cddf9148aa7",
    "date": "2026-04-16",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "Cinclus_Pharma_Arsredovisning_2025.pdf",
    "text_chars": 281267,
    "sha256": "7877b912af411f33be92b57647a1b704b119ac2f78845ef43255af100f8ac4bc",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 172584
      },
      {
        "number": 2,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 108681
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aaba771d2d1fe265b79612ee155efcae6",
    "date": "2026-02-18",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "Bokslutskommunike_2025.pdf",
    "text_chars": 95665,
    "sha256": "77b5757b975035b7c1264aa7d4b19696a6a8728fa9582c33f10ab218ab48c216",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 95665
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a05ae3e9c05f619a0eb7dfed28ab19159",
    "date": "2025-11-20",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "Interim_Report_Cinclus_Pharma_Jan_Sep_2025_1.pdf",
    "text_chars": 101924,
    "sha256": "5f0c61e5739da3cc0e59df0afcf8d5a3c7eb54a4ad52037bd6cb26409c5ae795",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 101924
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad3f2a1c26ea557b4f7522bb4bb94902f",
    "date": "2025-08-20",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "Delarsrapport_Cinclus_Pharma_Jan_Juni_2025_1.pdf",
    "text_chars": 95184,
    "sha256": "3bd0c85b4b77fcbd10ad07eeb719bb2a751b0bffa1f8e92dc8cee8e6a398e5d9",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 95184
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a522e89c5664a1db22371aaf9c69463d2",
    "date": "2025-05-20",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "Cinclus_Pharma_Delarsrapport_Kvartal_1_2025.pdf",
    "text_chars": 87832,
    "sha256": "8a85b0ab839af5e12c95b5c540a2c1f0ce44634266fe922ef66c78020ac0c5a6",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 87832
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a394e7e17c7b2dcdbe58c1dbb2ba29122",
    "date": "2025-04-30",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "Cinclus_Pharma_Arsredovisning_2024_2.pdf",
    "text_chars": 342936,
    "sha256": "7cd593a96ce1e297e8c56d2afc904a9d469fc924881517ad61a704f46ba0258e",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 178763
      },
      {
        "number": 2,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 164171
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7f80acd423cf29ac5a7847d13df1c03a",
    "date": "2025-02-20",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "Bokslutskommunike_2024_Cinclus_Pharma.pdf",
    "text_chars": 92082,
    "sha256": "89d722bc452c3b5e5ee60f575da7fc0b2883a79ec60c48cf27ccb461d70f8ae8",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 92082
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a44e5a06d73f6dbbffa3866facd8f337d",
    "date": "2024-11-14",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_September_2024.pdf",
    "text_chars": 91562,
    "sha256": "b7243893f5c7fb4ff2bf11960b9e4b96ac38a00df1c81cb01f7c4780a4ac51aa",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 91562
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7c94962bd25075b3f3ab2a4e60e68e9d",
    "date": "2024-08-29",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_Juni_2024.pdf",
    "text_chars": 87625,
    "sha256": "5c0f583e66122910127e5377ca850253b3f7b7a228c0138a5c8540b88987d2d1",
    "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 87625
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/cinclus-pharma-holding",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 2121,
    "sha256": "171bb0cf6acd4e9774563e8adf497e41e1f10da5c7b7170a3d86eae420a64bda",
    "url": "/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 2121
      }
    ]
  }
]